We have a seasoned leadership team with extensive experience in commercialization of ablation technologies.
Board of Directors
Profound Medical Inc., receives guidance and governance from a Board of Directors that embodies deep experience in the medical device industry and a strong history of success.
Arun Menawat – Chairman
Dr. Menawat joined Profound as Chief Executive Officer in August 2016 and has been a member of the Board for approximately two years prior to joining the Corporation. Previously. Dr. Menawat was the President and Chief Executive Officer of Novadaq Technologies Inc., for 13 years, guiding the company from a start-up to a fast growing, NASDAQ listed medical imaging company in North America, with a market cap of approximately $1 billion at the time of his departure. Previously, Dr. Menawat was President of Cedara, a medical imaging software company and held senior positions at Tenneco Inc. and Hercules Inc. Dr. Menawat currently serves on the board of directors of Stereotaxis and EIMindA and as an advisor to Baylis Medical. Dr. Menawat’s educational background includes a Ph.D. in Chemical Engineering, from the University of Maryland, College Park, MD, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University, Evanston, Illinois.oggle Content goes here
Arthur L. Rosenhal – Director
Dr. Rosenthal is director and Chair of Compensation Committee for LivaNova PLC, a UK global medical technology company. Prior, Dr. Rosenthal served on the Cyberonics board of directors as a non-executive director and Chair of the Compensation Committee from January 2007 to October 2015. Since June 2010, Dr. Rosenthal has served as Professor of Practice in the Biomedical Engineering Department at Boston University. Since December 2011, Dr. Rosenthal has also served as CEO of gEyeCue, Ltd., which he co-founded, a development stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. From June 2011 until July 2012, Arthur served as executive vice chairman of Cappella Medical Devices Ltd. (now ArraVasc Ltd.), a development-stage company focused on novel device solutions for coronary artery disease. From June 2009 until June 2011, Dr. Rosenthal served as President and CEO of Cappella, Inc. Arthur served as chairman, from January 2002, and CEO, commencing in January 2005, of Labcoat, Ltd. until its acquisition by Boston Scientific Corporation in December 2008. From January 1994 to May 2000, Dr. Rosenthal was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston Scientific, and from May 2000 until his retirement in January 2005, he was a Senior Vice President, Chief Scientific Officer, and Executive Committee Member of Boston Scientific. From 2000 until 2010, Arthur served as a non-executive director, and from 2006 through 2009, as chairman of the Remuneration Committee, of Renovo, Ltd., a U.K. based pharmaceutical company that became publicly traded in 2006. In July 2009, Arthur joined the board of Interface Biologics, Inc., a Toronto-based development stage company focused on drug delivery devices, as a non-executive director. In April 2011, Dr. Rosenthal was elected Chairman at Interface Biologics, Inc. From April 2013 to May 2015, Dr. Rosenthal served as non-executive director and Member of the Compensation Committee of Arch Technologies, Inc. and is currently and member of Arch’s Clinical Advisory Board. In 2015, Dr. Rosenthal was appointed to the Industrial Advisory Committee, CURAM (National University in Galway, Ireland). Dr. Rosenthal is a Fellow of the American Institute of Medical and Biological Engineering since 2003.
Brian Ellacott – Director
Mr. Ellacott is an experienced global medical device executive. Mr. Ellacott joined Belmont Instrument as Chief Executive Officer in December 2017. Belmont is a Boston based private equity owned medical device company with a leading global position in fluid warming and infusion systems. Prior to Belmont, Mr. Ellacott was the President and CEO of Laborie Medical Technologies (“Laborie”). Laborie is a Urology and Gastroenterology medical device company based in Toronto with manufacturing facilities in Toronto, Montreal, Enschede NL, Attikon Switzerland and Portsmouth New Hampshire. Mr. Ellacott joined private equity owned Laborie as President and CEO in July 2013 and in four years completed 14 global acquisitions tripling Laborie’s revenue and increasing EBITDA eight fold. The company was ranked as one of the fastest growing and most profitable medical device companies in the world. Prior to joining Laborie, Mr. Ellacott served as Executive Vice President and General Manager of Invacare’s (NYSE:IVC) $1 billion North and South American homecare and rehabilitation business. Mr. Ellacott has also held executive positions with Baxter International and American Hospital Supply, with assignments in Canada, Australia and the United States. Mr. Ellacott serves on the board of Belmont and is the past Chairman of the board of the Canadian Assistive Devices Association. Mr. Ellacott holds a Bachelor of Business Administration Degree from Laurier University, Waterloo, Ontario Canada and is a dual United States and Canadian citizen.
Jean-François Pariseau – Director
Mr. Pariseau is co-founder and Partner at Amplitude Ventures. Amplitude is a capital catalyst for highly innovative companies at the point of value acceleration. The Firm works with Canada’s most promising healthcare companies with a shared vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Before co-founding Amplitude, Jean-Francois was Partner at the Healthcare Fund of BDC Capital and an investment manager with CDP Capital Technology Ventures, a $2 billion global fund investing in healthcare, information technology and advanced technologies, where he was responsible for healthcare investments in Canada and the US. Prior to joining the investment world, Jean-Francois was CEO of a consulting company specializing in regulatory affairs, and VP, R&D for a pharmaceutical-product distribution company, both of which he founded. Mr. Pariseau holds a Bachelor of Science in Biotechnology from Université de Sherbrooke, a Master of Science in Biomedical Sciences from Université de Montréal, and an MBA from HEC Montréal. Jean-François currently sits on the Board of Directors of Profound Medical Inc. (TSX: PRN) and Imagia Inc (Chair).
Clinical Advisory Board
Profound Medical’s research and clinical trials are further informed by the considerable collective expertise of well-experienced clinicians, specializing in urology and radiology.
Peter Albertsen, Chief and Program Director of the Division of Urology, Professor of Surgery, University of Connecticut Health Center
Scott Eggener, Co-Director, Prostate Cancer Program Director, Translational and Outcomes Research, Section of Urology, Associate Professor of Surgery, University of Chicago
Adam Kibel, Chief of Urology, Brigham and Women’s Hospital Chief of Urology, Dana-Farber Cancer Institute, Professor of Surgery, Harvard Medical School, Dana-Farber/Harvard Cancer Center
Eric Klein, Chairman of the Glickman Urological and Kidney Institute, Professor of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic
We currently have openings
Clinical Application Specialist (EMEA) – Candidate should reside in Germany
Clinical Sales Specialist – North East U.S. – Candidate should reside in the North East U.S.
Customer Service Engineer (EMEA) - Candidate should reside in Germany
Embedded Software FPGA Developer – Vantaa, Finland
Field Service Engineer – Candidate should reside in the U.S.
Hardware (Electrical) Developer - Mississauga, Canada